Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | KCNQ4 | P56696 | 4/20 | 0.56 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20159076 | 0.87 | KCNQ4 (0.56) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL15996890 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL18575369 | 0.85 | ALDH1A1 (0.61) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL18600345 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL30494445 | 0.82 | KCNQ4 (0.60) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL18600341 | 0.82 | KCNQ4 (0.55) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL18575368 | 0.81 | KCNQ4 (0.59) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL18600344 | 0.81 | KCNQ4 (0.60) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL15996884 | 0.81 | KCNQ4 (0.78) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 | |
| SCHEMBL15996878 | 0.80 | KCNQ4 (0.79) | CYP1A2CYP2C8CYP2B6KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138833-B1 | NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-10316008-B2 | KCNQ potassium channel agonist, and preparation method therefor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180134677-A1 | NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20170081301-A1 | NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-03-23 | — | — | US | disclosed |
| EP-3138833-A1 | NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2017-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134677-A1 | NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KCNQ5, KCNQ4, KCNQ1 | CYP1A2 1348/4885CYP2C8 1692/4885CYP2B6 1423/4885 |
| US-10316008-B2 | KCNQ potassium channel agonist, and preparation method therefor and use thereof | KCNQ5, KCNQ4, KCNQ3 | CYP1A2 1139/4885CYP2C8 1423/4885CYP2B6 1397/4885 |
| US-20170081301-A1 | NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF | KCNQ5, KCNQ4, KCNQ3 | CYP1A2 950/4885CYP2C8 1512/4885CYP2B6 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.